144 related articles for article (PubMed ID: 37818332)
21. Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy.
Beck J; Rouleau M; Lemire F; Neveu B; Déry M; Thériault B; Dubois G; Guérette D; Pouliot F
Prostate; 2023 May; 83(7):670-677. PubMed ID: 36851864
[TBL] [Abstract][Full Text] [Related]
22. Prediction of Time to Castration-Resistant Prostate Cancer Using Bone Scan Index in Men with Metastatic Hormone-Sensitive Prostate Cancer.
Miyoshi Y; Yoneyama S; Kawahara T; Hattori Y; Teranishi JI; Ohta JI; Takebayashi S; Yokomizo Y; Hayashi N; Uemura H
Urol Int; 2017; 99(4):400-405. PubMed ID: 28609769
[TBL] [Abstract][Full Text] [Related]
23. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
24. SRD5A gene polymorphism in Japanese men predicts prognosis of metastatic prostate cancer with androgen-deprivation therapy.
Shiota M; Fujimoto N; Yokomizo A; Takeuchi A; Itsumi M; Inokuchi J; Tatsugami K; Uchiumi T; Naito S
Eur J Cancer; 2015 Sep; 51(14):1962-9. PubMed ID: 26169017
[TBL] [Abstract][Full Text] [Related]
25. Phenotypes of circulating tumour cells predict time to castration resistance in metastatic castration-sensitive prostate cancer.
Yang YJ; Kong YY; Li GX; Wang Y; Ye DW; Dai B
BJU Int; 2019 Aug; 124(2):258-267. PubMed ID: 30536520
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Lactate Dehydrogenase in Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Mori K; Kimura S; Parizi MK; Enikeev DV; Glybochko PV; Seebacher V; Fajkovic H; Mostafaei H; Lysenko I; Janisch F; Egawa S; Shariat SF
Clin Genitourin Cancer; 2019 Dec; 17(6):409-418. PubMed ID: 31558410
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic value of testosterone during androgene deprivation therapy].
Vallat A; Pillot P; Lebâcle C; Irani J
Prog Urol; 2019 Sep; 29(10):510-523. PubMed ID: 31311715
[TBL] [Abstract][Full Text] [Related]
28. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract][Full Text] [Related]
30. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
[TBL] [Abstract][Full Text] [Related]
31. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
Nishizawa K; Hattahara K; Onishi H; Yoshida T
Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
[TBL] [Abstract][Full Text] [Related]
32. Simple risk assessment in prostate cancer patients treated with primary androgen deprivation therapy: The Korean Cancer Study of the Prostate risk classification.
Choi SY; Ryu J; You D; Hong JH; Ahn H; Kim CS
Int J Urol; 2019 Jan; 26(1):62-68. PubMed ID: 30238513
[TBL] [Abstract][Full Text] [Related]
33. Effects of statin use on the response duration to androgen deprivation therapy in metastatic prostate cancer.
Jung J; Lee C; Lee C; Kwon T; You D; Jeong IG; Hong JH; Ahn H; Kim CS
Korean J Urol; 2015 Sep; 56(9):630-6. PubMed ID: 26366275
[TBL] [Abstract][Full Text] [Related]
34. PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate.
Ferraldeschi R; Nava Rodrigues D; Riisnaes R; Miranda S; Figueiredo I; Rescigno P; Ravi P; Pezaro C; Omlin A; Lorente D; Zafeiriou Z; Mateo J; Altavilla A; Sideris S; Bianchini D; Grist E; Thway K; Perez Lopez R; Tunariu N; Parker C; Dearnaley D; Reid A; Attard G; de Bono J
Eur Urol; 2015 Apr; 67(4):795-802. PubMed ID: 25454616
[TBL] [Abstract][Full Text] [Related]
35. An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223.
Sartor O; Coleman RE; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Vogelzang NJ; Bruland Ø; Kobina S; Wilhelm S; Xu L; Shan M; Kattan MW; Parker C
Ann Oncol; 2017 May; 28(5):1090-1097. PubMed ID: 28453701
[TBL] [Abstract][Full Text] [Related]
36. Effect of Prior Local Treatment and Prostate-Specific Antigen Kinetics during Androgen-Deprivation Therapy on the Survival of Castration-Resistant Prostate Cancer.
Hah YS; Lee JS; Rha KH; Hong SJ; Chung BH; Koo KC
Sci Rep; 2019 Aug; 9(1):11899. PubMed ID: 31417160
[TBL] [Abstract][Full Text] [Related]
37. The Role of PCA 3 as a Prognostic Factor in Patients with Castration-resistant Prostate Cancer (CRPC) Treated with Docetaxel.
Bourdoumis A; Chrisofos M; Stasinou T; Christopoulos P; Mourmouris P; Kostakopoulos A; Deliveliotis C
Anticancer Res; 2015 May; 35(5):3075-9. PubMed ID: 25964598
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Significance of Time to Castration Resistance in Patients With Metastatic Castration-sensitive Prostate Cancer.
Miyake H; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Anticancer Res; 2019 Mar; 39(3):1391-1396. PubMed ID: 30842173
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
[TBL] [Abstract][Full Text] [Related]
40. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
Hashimoto K; Tabata H; Shindo T; Tanaka T; Hashimoto J; Inoue R; Muranaka T; Hotta H; Yanase M; Kunishima Y; Takahashi A; Masumori N;
Urol Oncol; 2019 Jul; 37(7):485-491. PubMed ID: 31103335
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
